These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9783412)

  • 41. Activation and suppression of the proinflammatory immune response by Vibrio cholerae toxins.
    Satchell KJ
    Microbes Infect; 2003 Nov; 5(13):1241-7. PubMed ID: 14623020
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recombinant derivative of a naturally occurring non-toxinogenic Vibrio cholerae 01 expressing the B subunit of cholera toxin: a potential oral vaccine strain.
    Dasgupta U; Bhadra RK; Panda DK; Deb A; Das J
    Vaccine; 1994 Mar; 12(4):359-64. PubMed ID: 8178559
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Moving forward with an imperfect vaccine.
    Pezzoli L; Azman AS
    Lancet Infect Dis; 2021 Oct; 21(10):1339-1341. PubMed ID: 34146474
    [No Abstract]   [Full Text] [Related]  

  • 44. [Cholera immunology and the molecular biology of cholera toxin. Recent progress and future prospects].
    Carrada Bravo T
    Rev Alerg; 1993; 40(4):91-4. PubMed ID: 8143024
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunity in experimental cholera: effect of parenteral immunization with vaccines and toxoid.
    Sinha VB; Bhaskaran K
    Bull World Health Organ; 1973; 49(6):605-13. PubMed ID: 4548387
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of a live oral cholera vaccine in human volunteers.
    Woodward WE; Gilman RH; Hornick RB; Libonati JP; Cash RA
    Dev Biol Stand; 1976; 33():108-12. PubMed ID: 782960
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Texas Star-SR: attenuated "Vibrio cholerae" oral vaccine candidate.
    Levine MM; Black RE; Clements ML; Young CR; Lanata C; Sears S; Honda T; Finkelstein R
    Dev Biol Stand; 1983; 53():59-65. PubMed ID: 6873477
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cholera vaccines.
    Tacket CO; Clemens J; Kaper JB
    Biotechnology; 1992; 20():53-68. PubMed ID: 1600389
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Infection and immunity to Vibrio cholerae, Salmonella typhimurium and Escherichia coli in a rabbit model.
    Guinée PA; Jansen WH; Rijpkema SG
    Zentralbl Bakteriol Mikrobiol Hyg A; 1988 Nov; 270(1-2):260-9. PubMed ID: 2464884
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunologic response to oral cholera vaccination in a crossover study: a novel placebo effect.
    Wasserman SS; Kotloff KL; Losonsky GA; Levine MM
    Am J Epidemiol; 1993 Dec; 138(11):988-93. PubMed ID: 8256784
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Live Attenuated Cholera Vaccine CVD 103-HgR Primes Responses to the Toxin-Coregulated Pilus Antigen TcpA in Subjects Challenged with Wild-Type Vibrio cholerae.
    Mayo-Smith LM; Simon JK; Chen WH; Haney D; Lock M; Lyon CE; Calderwood SB; Kirkpatrick BD; Cohen M; Levine MM; Gurwith M; Harris JB
    Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27847368
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Current developments with cholera vaccines: "Where do we go from here?".
    Finkelstein RA
    Prog Clin Biol Res; 1980; 47():133-42. PubMed ID: 7010372
    [No Abstract]   [Full Text] [Related]  

  • 53. Pathogenic and vaccine significance of toxin-coregulated pili of Vibrio cholerae E1 Tor.
    Attridge SR; Voss E; Manning PA
    J Biotechnol; 1999 Aug; 73(2-3):109-17. PubMed ID: 10486921
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Construction of an engineered bivalent vaccine strain consisting of Vibrio cholerae CT-B and LPS-O antigens.
    Yu X; Ma Q
    Chin J Biotechnol; 1994; 10(4):225-32. PubMed ID: 7780018
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Suppressive effects of IgE antibody formation of orally administered living and killed Vibrio cholerae cells in mice].
    Komagata Y
    Kansenshogaku Zasshi; 1984 Apr; 58(4):318-26. PubMed ID: 6434656
    [No Abstract]   [Full Text] [Related]  

  • 56. Cholera vaccines: WHO position paper – August 2017.
    Wkly Epidemiol Rec; 2017 Aug; 92(34):477-98. PubMed ID: 28845659
    [No Abstract]   [Full Text] [Related]  

  • 57. Acid-detoxified Inaba lipopolysaccharide (pmLPS) is a superior cholera conjugate vaccine immunogen than hydrazine-detoxified lipopolysaccharide and induces vibriocidal and protective antibodies.
    Grandjean C; Wade TK; Ropartz D; Ernst L; Wade WF
    Pathog Dis; 2013 Mar; 67(2):136-58. PubMed ID: 23620159
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lack of cross-protection against diarrhea due to Vibrio cholerae O1 after oral immunization of rabbits with V. cholerae O139 Bengal.
    Albert MJ; Alam K; Rahman AS; Huda S; Sack RB
    J Infect Dis; 1994 Mar; 169(3):709-10. PubMed ID: 8158063
    [No Abstract]   [Full Text] [Related]  

  • 59. New attenuated derivatives of Vibrio cholerae.
    Pearson GD; DiRita VJ; Goldberg MB; Boyko SA; Calderwood SB; Mekalanos JJ
    Res Microbiol; 1990; 141(7-8):893-9. PubMed ID: 2101479
    [No Abstract]   [Full Text] [Related]  

  • 60. Colonization & protection in infant rabbits by a choleragenoid producing strain of Vibrio cholerae.
    Sinha VB; Srivastava BS
    Indian J Med Res; 1986 Aug; 84():139-41. PubMed ID: 3759164
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.